Shamina Rangwala is the Global Lead for Internal Medicine in the Emerging Science & Innovation group at Pfizer. In this role, she uses her extensive expertise and network in drug discovery and development to identify novel therapies and technologies for the treatment of cardiovascular and metabolic disease.

Shamina received her Ph.D. in Pharmacology at The Ohio State University and completed her post-doctoral fellowship with Dr. Mitch Lazar at the University of Pennsylvania, where her research interests focused on the role of PPARs and adipokines on body weight and insulin resistance. Since leaving Penn, Shamina has worked in drug discovery at several large pharmaceutical companies in positions of increasing responsibility, including Novartis and Novo Nordisk. Prior to joining Pfizer, she worked at Janssen/JNJ – initially as a team leader in Cardiovascular and Metabolic Research, where she led two programs into early clinical development, and subsequently at the JNJ Innovation Center in London, where she led efforts in identifying external opportunities in cardiometabolic and retinal diseases in Europe.